Prognostic factors and the prognostic role of inflammation indices in malignant pleural mesothelioma.
Inflammation indices
malignant pleural mesothelioma
prognostic nutritional index
prognostic score
Journal
Turk gogus kalp damar cerrahisi dergisi
ISSN: 1301-5680
Titre abrégé: Turk Gogus Kalp Damar Cerrahisi Derg
Pays: Turkey
ID NLM: 100887967
Informations de publication
Date de publication:
Jan 2023
Jan 2023
Historique:
received:
02
02
2022
accepted:
04
04
2022
entrez:
17
3
2023
pubmed:
18
3
2023
medline:
18
3
2023
Statut:
epublish
Résumé
In this study, we aimed to investigate the prognostic factors of malignant pleural mesothelioma and the prognostic value of inflammation indices in malignant pleural mesothelioma. Between January 2002 and December 2019, a total of 132 patients (74 males, 58 females; mean age: 55 years; range, 31 to 79 years) diagnosed with malignant pleural mesothelioma were retrospectively analyzed. Patients" demographic data and laboratory results were recorded. The prognostic value of the following five inflammation indices was evaluated: neutrophil-to-lymphocyte ratio, platelet-to-lymphocyte ratio, advanced lung cancer inflammation index, C-reactive protein/albumin ratio, and prognostic nutritional index. Of all patients, 81% (n=107) were aged 65 or older and 61.4% (n=81) had an epithelioid histology. Of 12 variables examined in the multivariate analysis for their relationship with survival, age ≥65 years, non-epithelioid subtype, and prognostic nutritional index <40 were found to be poor prognostic factors. Based on the score constructed from these factors, the good prognostic group (score 0-1) had a median overall survival of 21 months and a one-year survival rate of 77.9%, while the poor prognostic group (score 2-3) had a median overall survival of nine months and a one-year survival rate of 29.7%. Our study results indicate that age ≥65 years, prognostic nutritional index <40, and non-epithelioid histological subtype are poor prognostic factors of malignant pleural mesothelioma.
Sections du résumé
Background
UNASSIGNED
In this study, we aimed to investigate the prognostic factors of malignant pleural mesothelioma and the prognostic value of inflammation indices in malignant pleural mesothelioma.
Methods
UNASSIGNED
Between January 2002 and December 2019, a total of 132 patients (74 males, 58 females; mean age: 55 years; range, 31 to 79 years) diagnosed with malignant pleural mesothelioma were retrospectively analyzed. Patients" demographic data and laboratory results were recorded. The prognostic value of the following five inflammation indices was evaluated: neutrophil-to-lymphocyte ratio, platelet-to-lymphocyte ratio, advanced lung cancer inflammation index, C-reactive protein/albumin ratio, and prognostic nutritional index.
Results
UNASSIGNED
Of all patients, 81% (n=107) were aged 65 or older and 61.4% (n=81) had an epithelioid histology. Of 12 variables examined in the multivariate analysis for their relationship with survival, age ≥65 years, non-epithelioid subtype, and prognostic nutritional index <40 were found to be poor prognostic factors. Based on the score constructed from these factors, the good prognostic group (score 0-1) had a median overall survival of 21 months and a one-year survival rate of 77.9%, while the poor prognostic group (score 2-3) had a median overall survival of nine months and a one-year survival rate of 29.7%.
Conclusion
UNASSIGNED
Our study results indicate that age ≥65 years, prognostic nutritional index <40, and non-epithelioid histological subtype are poor prognostic factors of malignant pleural mesothelioma.
Identifiants
pubmed: 36926157
doi: 10.5606/tgkdc.dergisi.2023.23365
pmc: PMC10012989
doi:
Types de publication
Journal Article
Langues
eng
Pagination
105-115Informations de copyright
Copyright © 2023, Turkish Society of Cardiovascular Surgery.
Déclaration de conflit d'intérêts
Conflict of Interest: The authors declared no conflicts of interest with respect to the authorship and/or publication of this article.
Références
Asian Pac J Cancer Prev. 2014;15(5):2061-7
pubmed: 24716935
Ann N Y Acad Sci. 2010 Aug;1203:7-14
pubmed: 20716277
Chest. 1998 Mar;113(3):723-31
pubmed: 9515850
Ther Clin Risk Manag. 2016 Apr 22;12:651-6
pubmed: 27217757
J Clin Oncol. 1989 Aug;7(8):1157-68
pubmed: 2666592
Cancers (Basel). 2021 Feb 06;13(4):
pubmed: 33562138
Turk Gogus Kalp Damar Cerrahisi Derg. 2021 Jan 13;29(1):92-100
pubmed: 33768986
Cancer. 1993 Jul 15;72(2):394-404
pubmed: 8319171
Oncotarget. 2017 Feb 16;8(34):57460-57469
pubmed: 28915685
J Clin Oncol. 1988 Jan;6(1):147-53
pubmed: 3335886
Cancer. 1993 Jul 15;72(2):410-7
pubmed: 8319172
Int J Cancer. 1988 Apr 15;41(4):525-30
pubmed: 3356487
MMWR Morb Mortal Wkly Rep. 2017 Mar 03;66(8):214-218
pubmed: 28253224
Occup Environ Med. 1997 Jun;54(6):403-9
pubmed: 9245946
Clin Cancer Res. 2010 Dec 1;16(23):5805-13
pubmed: 20956618
Ann Surg Oncol. 2018 Jun;25(6):1555-1563
pubmed: 29500763
J Clin Oncol. 1998 Jan;16(1):145-52
pubmed: 9440736
J Cancer Res Clin Oncol. 2013 Dec;139(12):2117-23
pubmed: 24149776
Clin Respir J. 2018 Jun;12(6):2013-2019
pubmed: 29356383
Gastroenterol Res Pract. 2019 Feb 04;2019:7103915
pubmed: 30863440
Br J Ind Med. 1960 Oct;17:260-71
pubmed: 13782506
Eur Respir J. 2011 Dec;38(6):1420-4
pubmed: 21737558